Specialists of the Russian nuclear industry have begun preclinical trials of a radiopharmaceutical drug for the "targeted" destruction of prostate cancer. The scale of the spread of oncological diseases requires the use of new radioactive isotopes for their treatment. Such isotopes are recognized as so-called alpha emitters, which effectively kill …